Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381341 · ClinicalTrials.gov registry record · Phase 1
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01381341: Completed Phase 1 study, sponsored by Abbott.
NCT01381341 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01381341, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
A pharmacokinetic study to compare 2 clinical formulations of linifanib.
Primary Outcome
Blood samples for the pharmacokinetics (PK) of linifanib will be collected at designated time points and assayed.
Interventions
- DRUG linifanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT01381341 record still lists
NCT01381341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which linifanib is the first listed.
NCT01381341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01381341 about?
NCT01381341 is a clinical study titled "To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.". A pharmacokinetic study to compare 2 clinical formulations of linifanib.
What is the current status of trial NCT01381341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-05. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01381341?
The interventions under investigation include: linifanib (DRUG).
Who is sponsoring clinical trial NCT01381341?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01381341's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia